Continued growth and adoption of the SpineJack® in Q2 2017

Continued growth and adoption of the SpineJack® in Q2 2017

11 July 2017 / 18 h 00

+23% growth in sales in Q2, up to €5.7 million:
-- Strong International growth: +50% up to €0,7M
-- Continued growth in Europe: +20% up to €5M
-- Sales increased by 21% in the first half of 2017, reaching €10.3 million
-- More than 50,000 SpineJack® implants sold since 2011

Toulouse, July 11th, 2017 (6:00 PM CEST) – VEXIM (FR0011072602 – ALVXM), a medical device company specializing in the minimally invasive treatment of vertebral fractures, today announces its consolidated sales results for the second quarter, as of June 30th, 2017.

VEXIM sales performance in the second quarter is in line with our expectations. VEXIM is growing substantially in all regions in Europe and around the world. We expect a strong growth of our business in the second half of the year, meeting our business objectives and aiming at financial break-even for the year 2017“, said Vincent Gardès, CEO of VEXIM.


Continued growth in the second quarter 2017



€5.7 million in sales, VEXIM continues to expand in all geographies


In Europe, VEXIM’s business continues to grow substantially reaching €9.3 million in the first half of 2017, representing a 18% growth compared to the same period in 2016. Since 2016, sales have increased in all countries and are progressing according to plan.


Outside of Europe, where quarterly sales increased 50% over the same period last year, VEXIM continues to see growing interest in the SpineJack® technology. As previously announced, VEXIM is in the process of launching SpineJack® products in Brazil and anticipates a continued strong growth in sales in the second part of 2017.

Financial reporting schedule
2017 half-year results: September 14th, 2017*
*(Indicative date, subject to changes)

  1. Cf. segment reporting applied since VEXIM switched to IFRS consolidated financial statements.